Commercialization


  • Cliff jump
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Big Pharma earnings hang hope on the next generation of blockbusters

    Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.

    By Oct. 31, 2024
  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Backlash builds against Novo’s Catalent takeover

    Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.

    By Oct. 30, 2024
  • PV100 category rare disease warriors
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Rare Disease Warriors

    Pharma pros driving drug development and access for patients with high unmet needs. 

    By Oct. 29, 2024
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J’s comeback kid Spravato heads for blockbuster status

    After a slow start, the novel esketamine nasal spray for depression is now J&J’s fastest-growing medication.

    By Oct. 25, 2024
  • Dengue vax
    Image attribution tooltip
    Buda Mendes via Getty Images
    Image attribution tooltip

    Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?

    As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.

    By Alexandra Pecci • Oct. 23, 2024
  • heart monitor chart
    Image attribution tooltip
    PharmaVoice/PharmaVoice
    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Cardiometabolic All-Stars

    Leaders tackling long-standing health needs with new solutions.

    By Oct. 18, 2024
  • Corporate logos are seen outside  on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    Want to launch a blockbuster? An AstraZeneca exec breaks it down.

    Even drugs with “blockbuster potential” often fall short of expectations. Here’s what can help a new medication pass the $1 billion mark.

    By Alexandra Pecci • Oct. 16, 2024
  • bottle of Rezdiffra
    Image attribution tooltip
    Courtesy of Madrigal
    Image attribution tooltip

    How Madrigal plans to win on the market with the first MASH drug

    Despite the drug’s wide patient pool, Madrigal is taking a targeted approach with its first launch.

    By Oct. 10, 2024
  • A photo of Bluebird bio signage in a corporate lobby
    Image attribution tooltip
    Permission granted by Bluebird bio
    Image attribution tooltip

    Bluebird to lay off another 25% of workforce in latest restructuring

    The announced job cuts are the latest in a series of steps Bluebird has taken to preserve cash and break even financially amid slow uptake of its marketed gene therapies.

    By Delilah Alvarado • Sept. 25, 2024
  • world map pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Patient access: How Novartis, Eli Lilly, and other Big Pharmas measure up

    A new report examines the patient reach efforts of 20 of the world’s largest pharma companies in low- and middle-income countries.

    By Alexandra Pecci • Sept. 23, 2024
  • Scientist suit handshake
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    At J&J, oncology R&D meets commercial strategy in a quest for new standards of care

    The disparate teams of research and commercial at J&J work closely together from the get-go.

    By Sept. 19, 2024
  • Pharmaceutical cartons with the logo for Bristol Myers Squibb's Opdivo rest on a refrigerator shelf.
    Image attribution tooltip

    George Frey/Reuters

    Image attribution tooltip
    Deep Dive

    A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

    Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

    By Jonathan Gardner • Sept. 10, 2024
  • Drug money
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    A new way of determining a drug’s value — with health equity in mind

    Quality-adjusted life years are an important tool to frame a drug’s cost effectiveness, but they leave out other determinants of health. 

    By Sept. 10, 2024
  • Front sign of FDA building
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA adcomm reform talks heat up

    As the agency considers eliminating adcomm votes from the approval process, members vie to have their voices heard.

    By Sept. 3, 2024
  • test tube dollar
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Is anyone taking the world’s priciest drugs?

    A slew of breakthrough gene therapies won FDA approval in recent years — but high price tags haven’t always yielded big returns.

    By Aug. 30, 2024
  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical
    Image attribution tooltip

    BioMarin taps Amgen, Roche vets in executive reshuffle

    Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.

    By Jacob Bell • Aug. 22, 2024
  • Image attribution tooltip
    Courtesy of 23andMe
    Image attribution tooltip
    Q&A

    23andMe inches closer to cancer immunotherapy, guided by its genetic database

    Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.

    By Aug. 20, 2024
  • A line of paper figures and one crumpled cut off.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    M&A is ready to explode, and that’s good news for pharma layoffs

    Deals driven by obesity meds are fueling an M&A comeback, driving the industry to take fewer cost-cutting measures.

    By Kelly Bilodeau • Aug. 12, 2024
  • Horse race
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip

    Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half

    The top drugs at each of the world’s most valuable pharma companies tell the story of just how much the industry has changed over the course of a few years.

    By Aug. 8, 2024
  • A product image of Moderna's RSV shot mRESVIA in its packaged box with syringe in front of the box
    Image attribution tooltip
    Permission granted by Moderna
    Image attribution tooltip

    Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback

    An advisory committee’s age group recommendations look like a major setback, but executives are painting a rosier picture.

    By Aug. 6, 2024
  • Sanofi and Regeneron's Dupixent
    Image attribution tooltip
    Permission granted by Sanofi
    Image attribution tooltip

    7 years after launch, Sanofi’s Dupixent is set for a megablockbuster run

    Dupixent hasn’t generated as much buzz as top-sellers like Keytruda or Ozempic, but the drug is boosting Sanofi’s earnings into the future.

    By July 30, 2024
  • pin on calendar out of focus
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Citius’ first FDA decision date is approaching — and its CEO has millions on the line

    Citius Pharmaceuticals CEO Leonard Mazur has personally invested $22.5 million into the company, which is fast approaching a potential turning point.

    By July 26, 2024
  • BMS corporate sign
    Image attribution tooltip
    Courtesy of BMS
    Image attribution tooltip

    BMS’ long-standing leukemia blockbuster stares down its first generic

    Patent disputes in the U.S. and abroad have opened the door to new generics ready for launch as soon as September for BMS’ Sprycel.

    By July 12, 2024
  • Congressman Garcia gestures to a cardboard meme of two identical Spiderman characters pointing at one another.
    Image attribution tooltip
    Rebecca Pifer/PharmaVoice
    Image attribution tooltip

    As feds crack down on PBMs for drug costs, Big Pharma could lose some of the heat

    Drugmakers pointed the finger at PBMs for being the culprit behind rising drug prices in the U.S. for years — now, an ongoing FTC investigation has their back.

    By July 11, 2024
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip

    As the GLP-1 market booms, other healthcare companies are cashing in

    With more Americans taking obesity medications, adjacent businesses are offering supportive services to offset side effects, collect data and foster new health benefits.

    By July 10, 2024